- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03858257
High Flow Nasal Oxygen During Sedation
9. listopadu 2020 aktualizováno: Aaron Conway, University Health Network, Toronto
High Flow Nasal Oxygen During Conscious Sedation in the Cardiac Catheterisation Laboratory: A Randomized Controlled Trial
The primary objective of this study is to test the hypothesis that using high flow nasal oxygen improves ventilation during cardiac implantable electronic device procedures performed with conscious sedation.
A randomized controlled trial design will be used with participants randomized in a 1:1 ratio to oxygen supplementation through a standard facemask or high flow nasal oxygen.
Přehled studie
Postavení
Dokončeno
Podmínky
Intervence / Léčba
Detailní popis
High flow nasal oxygen (HFNO) is increasingly regarded as a promising technology for oxygen delivery in critical care and anesthetic management.
Although promising, further high-quality studies examining the effects of using HFNO during procedural sedation are required to inform decision-making regarding implementation of this new technology into practice.
The 2018 guidelines from the American Society of Anesthesiology stated that there is insufficient evidence regarding which methods of supplemental oxygen administration (e.g., nasal cannula, face mask, or specialized devices such as HFNO) are more effective.
This trial will address this limitation in the evidence base specifically in regard to the efficacy of using HFNO during conscious sedation in the cardiac catheterisation laboratory.
Typ studie
Intervenční
Zápis (Aktuální)
129
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Ontario
-
Toronto, Ontario, Kanada
- Toronto General Hospital
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
16 let a starší (Dítě, Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion criteria:
1. Adults undergoing an elective cardiac implantable electronic device procedure in the Peter Munk Cardiac Centre Cardiac Cath Labs with conscious sedation administered by an Anesthetic Assistant (de novo and replacement/revision procedures).
Exclusion criteria:
- Under 16 years of age.
- Underlying condition requiring chronic oxygen supplementation.
- Diagnosed respiratory condition with confirmed current hypercapnia.
- Pre-existing untreated pneumothorax.
- Transesophageal echocardiography planned for the procedure.
- Active nasal bleeding.
- Complete nasal obstruction.
- Recent upper airway surgery or base of skull fracture.
- Previous participation in the study.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Výzkum zdravotnických služeb
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: High flow nasal oxygen
The gas temperature will commence at the 'High' setting (ranges 30-32º Celsius) and titrated downwards if the patient complains of irritation.
The gas flow rate will commence at 30 liters per minute prior to sedation administration and be titrated up to 70 liters per minute as tolerated by the patient after sedation has been administered.
The fraction of oxygen in the gas will be commenced at 50% (same as that delivered from 6 liters per minute via facemask) and can be titrated upward according to patient requirements (i.e.
increased if there is evidence of hypoventilation, airway obstruction or inadequate oxygenation, decreased during use of diathermy).
Anesthesia Assistants at the site will be provided with training in the use of this mode of oxygen delivery prior to study commencement.
|
The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used.
|
|
Jiný: Standard oxygenation
Supplemental oxygen through a facemask with the flow rate chosen by the clinician responsible for sedation as per their standard practice.
The oxygen flow rate is typically commenced at 6 liters per minute and can be titrated up to 15 liters per minute.
|
Supplemental oxygen through a facemask.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Peak transcutaneous carbon dioxide (TcCO2) concentration.
Časové okno: From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
Continuous measurements will be recorded using the Sentec Digital Monitoring with VSign 2 sensor.
|
From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean transcutaneous carbon dioxide concentration
Časové okno: From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
Continuous measurements will be recorded using the Sentec Digital Monitoring with VSign 2 sensor.
|
From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
|
Area under SpO2 90% oxygen desaturation curve
Časové okno: From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
Percentage of hemoglobin saturated with oxygen (SpO2) will be measured continuously throughout procedures as part of routine clinical practice through the anaesthetic machine.
This is a composite measure comprising the incidence, depth, and duration of oxygen desaturation events.
Area under SpO2 90% oxygen desaturation curve is calculated as the difference between the threshold (90%) and actual oxygen saturation (SpO2) summed every second during which oxygen saturation was below threshold.
|
From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
|
Adverse sedation events
Časové okno: From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
The Anaesthesia Assistant will be asked to complete the Tracking and reporting outcomes of procedural sedation (TROOPS) tool at the end of procedures.
Completion of the tool requires identification and description of the adverse event, the intervention, the outcome and the overall severity of the adverse event.
|
From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
|
Patient satisfaction with sedation: Iowa Satisfaction with Anesthesia Scale
Časové okno: After the participant has reached phase 2 post-anesthetic recovery. Estimated to be 30 minutes after procedure has finished.
|
Iowa Satisfaction with Anesthesia Scale.
Score ranges from -3 (worse satisfaction) to +3 (better satisfaction).
|
After the participant has reached phase 2 post-anesthetic recovery. Estimated to be 30 minutes after procedure has finished.
|
|
Costs associated with oxygen delivery
Časové okno: From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
Anesthesia Assistants will document devices used for supplemental oxygen delivery and airway management in both groups as per their usual practice in the anesthesia monitoring system.
|
From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
|
Anesthesia Assistant rating of difficulty maintaining the patient's oxygenation status
Časové okno: To be completed as soon as possible after the end of the procedure (within about 5 minutes).
|
The Anaesthesia Assistant will be asked to rate their perceived level of difficulty in maintaining oxygenation using a 6-level rating scale with ratings of "extremely difficult", "very difficult", "difficult", "easy", "very easy", "extremely easy".
|
To be completed as soon as possible after the end of the procedure (within about 5 minutes).
|
|
Anesthesia Assistant rating of difficulty using oxygen delivery device
Časové okno: To be completed as soon as possible after the end of the procedure (within about 5 minutes).
|
The Anaesthesia Assistant will be asked to rate their perceived level of difficulty using the oxygen delivery device using a 6-level rating scale with ratings of "extremely difficult", "very difficult", "difficult", "easy", "very easy", "extremely easy".
|
To be completed as soon as possible after the end of the procedure (within about 5 minutes).
|
|
Patient comfort of oxygen delivery
Časové okno: After the participant has reached phase 2 post-anesthetic recovery. Estimated to be 30 minutes after procedure has finished.
|
Participants will be asked to rate at the end of procedures their perceived overall comfort with the oxygen delivery device used during the procedure using a 6-level rating scale with ratings of 'maximal discomfort', 'very uncomfortable', 'uncomfortable', 'comfortable', 'very comfortable' and 'maximal comfort'.
|
After the participant has reached phase 2 post-anesthetic recovery. Estimated to be 30 minutes after procedure has finished.
|
|
Trajectory of transcutaneous carbon dioxide as a function of time
Časové okno: From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
Continuous measurements will be recorded using the Sentec Digital Monitoring with VSign 2 sensor
|
From the time between first sedative medication administration to the end of the procedure. Estimated duration of procedures is 30 minutes to 120 minutes.
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Vyšetřovatelé
- Vrchní vyšetřovatel: Aaron Conway, RN, PhD, University Health Network, Toronto
Publikace a užitečné odkazy
Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Aktuální)
7. srpna 2019
Primární dokončení (Aktuální)
12. března 2020
Dokončení studie (Aktuální)
12. března 2020
Termíny zápisu do studia
První předloženo
25. února 2019
První předloženo, které splnilo kritéria kontroly kvality
27. února 2019
První zveřejněno (Aktuální)
28. února 2019
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
12. listopadu 2020
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
9. listopadu 2020
Naposledy ověřeno
1. listopadu 2020
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 18-6343
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
ANO
Popis plánu IPD
Study data, participant-level data sets (without identifying information) and code for statistical analyses will be shared in a publicly accessible repository at the time of publication.
Časový rámec sdílení IPD
With publication of results.
Kritéria přístupu pro sdílení IPD
Available through a public repository
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
- ANALYTIC_CODE
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .